Fact of Medicine
Brand Name: Poteligeo
Innovator Brand Name: Poteligeo
API: Mogamulizumab-kpkc
Packaging: 1 Vial (Per Box)
Strength: 20mg/5ml
Manufacturer Name: Kyowa Kirin, Inc.

Get Price


Mogamulizumab Medication

Poteligeo (Mogamulizumab) is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody used to treat adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy.

Dosage: The recommended dose of Poteligeo injection is 1 mg/kg. It should be administered as an intravenous infusion over minimum an hour. Administer on days 1’st, 8’th, 15’th, and 22’nd of the first 28-day cycle, then on days 1’st and 15’th of each subsequent 28-day cycle until the disease is progressive or observes any unacceptable toxicity. Take mogamulizumab within two days of the scheduled dose. In case a dose is missed, take the next dose promptly and resume the dosing schedule. Avoid taking it subcutaneously or by rapid intravenous administration.

Side Effects: The most commonly reported mogamulizumab side effects may include:

  • Rash
  • Infusion related reactions
  • Fatigue
  • Diarrhea
  • Musculoskeletal pain
  • Upper respiratory tract infection

Warnings and Precautions:

  • Patients with poteligeo dosage should be monitored for rash throughout the treatment course.
  • Patients while on poteligeo treatment are recommended to be monitored for the signs/symptoms of infection and must be treated promptly.
  •  Patients receiving poteligeo injection therapy should be closely monitored for signs/symptoms of the infusion reactions and the infusion should be interrupted for any grade reaction.
  • Use of mogamulizumab injection should be avoided during pregnancy or in those females of childbearing age who are not considering contraception.
  •  Females of reproductive age should be verified pregnancy status prior to strat the with mogamulizumab-kpkc.

More info

Storage: Store the vials of mmogamulizumab under refrigeration at 2°C to 8°C (36°F to 46°F) in the original package in order to protect from light until the time of use. Neither freeze nor shake this medication . Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship POTELIGEO at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the POTELIGEO Injections. Buying Procedure: In order to buy POTELIGEO, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: along with your Identity Proof, Legitimate Prescription and Medical Reports. Conclusion: Introduced as a monoclonal antibody, Poteligeo (Mogamulizumab) is used in the treatment of adults with relapsed or refractory MF or SS following at least one prior systemic therapy. In an open-label, multi center, randomized, phase-3 study, treatment with mogamulizumab injection resulted in superior PFS, improved ORR and longer duration of response in comparison to Zolinza.


What is Poteligeo? Poteligeo is a prescription agent used to treat mycosis fungoides (MF) or Sézary syndrome (SS) in adult recipients who have earlier taken treatment with at least one prior medication (administered by mouth or injection) that was not useful or in whom the disease has come back. What does Poteligeo contain as an active substance? The medication Poteligeo specifically contains the active substance Mogamulizumab-kpkc. Is Mogamulizumab an FDA approved drug? Yes, Mogamulizumab is an FDA approved drug. How much does poteligeo cost? The poteligeo price in India usually may vary depending on the wholesaler/pharmacy you visit and of course the brand you choose. What is the best price of Mogamulizumab? Please contact Toll-free: +91 1800 889 1064|+919310090915 for mogamulizumab price in India. We take guarantee of quality as well as delivery anywhere in the world as per the buyer’s requirements. Can I get Poteligeo (Mogamulizumab) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Poteligeo (Mogamulizumab), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.